文献速递新生儿儿童消化与营养

早产儿母乳强化:早产儿配方粉与母乳强化剂的随机非劣效试验

Fortification of Breast Milk With Preterm Formula Powder vs Human Milk Fortifier in Preterm Neonates: A Randomized Noninferiority Trial.
PubMed 文献 · JAMA Pediatr · 2021-01-01

结果显示PTF组体重增长15.7 g/kg/d,HMF组16.3 g/kg/d,均值差-0.5 g/kg/d(95%CI -1.9至0.7),95%CI下限未超过预设非劣效界值2 g/kg/d,且PTF组喂养不耐受发生率更低。

要点

  • PTF强化母乳在短期体重增长方面非劣效于HMF,均值差-0.5 g/kg/d(95%CI -1.9至0.7)。
  • PTF组喂养不耐受发生率更低(1.4 vs 6.8/1000患者日;IRR 0.19,95%CI 0.04至0.95)。
  • PTF组需停用强化≥24小时的新生儿更少(5% vs 22%;RR 0.22,95%CI 0.07至0.75)。

核心结论

  • 在早产极低出生体重儿中,使用早产儿配方粉强化母乳在短期体重增长方面不劣于使用母乳强化剂。
  • 考虑到喂养不耐受可能减少且成本更低,早产儿配方粉可能是资源有限环境下更好的强化选择。

研究设计与样本

  • 开放标签、非劣效、随机对照试验,2017年12月至2019年6月在印度一家三级新生儿病房开展。
  • 纳入标准为接受至少100 mL/kg/d喂养且其中75%以上为挤出母乳的早产极低出生体重儿。

主要发现

  • PTF组与HMF组平均(SD)体重增长分别为15.7(3.9)与16.3(4.0)g/kg/d,均值差-0.5 g/kg/d(95%CI -1.9至0.7)。
  • 95%CI下限未超过预设非劣效界值2 g/kg/d。
  • 喂养不耐受发生率PTF组为1.4/1000患者日,HMF组为6.8/1000患者日(IRR 0.19,95%CI 0.04至0.95)。
  • 需停用强化≥24小时的新生儿比例PTF组为5%,HMF组为22%(RR 0.22,95%CI 0.07至0.75)。
  • 坏死性小肠结肠炎II期及以上发生率(0 vs 5%)和宫外生长迟缓发生率(73% vs 81%)两组相当。

关键数值与推荐

  • 主要结局为至出院或矫正胎龄40周(以较早者为准)的体重增长,预设非劣效界值为2 g/kg/d。
  • PTF组补充钙、磷、铁、维生素D和多种维生素,HMF组仅补充维生素D以达到推荐膳食摄入量。

临床怎么用

  • 在资源有限环境中,可考虑用早产儿配方粉替代母乳强化剂强化母乳,以降低成本和喂养不耐受风险。
  • 强化时需注意PTF组额外补充钙、磷、铁、维生素D和多种维生素,而HMF组仅需补充维生素D。

局限性

  • 本研究为开放标签设计,未设盲。
  • 单中心研究,样本量123例,结论外推需谨慎。
  • 随访仅至出院或矫正胎龄40周,未评估长期生长和神经发育结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Fortification of expressed breast milk (EBM) using commercially available human milk fortifiers (HMF) increases short-term weight and length in preterm very low-birth-weight (VLBW) neonates. However, the high cost and increased risk of feed intolerance limit their widespread use. Preterm formula powder fortification (PTF) might be a better alternative in resource-limited settings. OBJECTIVE: To demonstrate that fortification of EBM by preterm formula powder is noninferior to fortification by HMF, in terms of short-term weight gain, in VLBW neonates. DESIGN, SETTING, AND PARTICIPANTS: Open-label, noninferiority, randomized trial conducted from December 2017 to June 2019 at a level 3 neonatal unit in India. The trial enrolled preterm (born at or before 34 weeks of gestation) VLBW neonates receiving at least 100 mL/kg/d of feeds and consuming 75% of milk or more as EBM. INTERVENTIONS: Neonates were randomly assigned to receive fortification by either PTF or HMF. Calcium, phosphorus, iron, vitamin D, and multivitamins were supplemented in PTF and only vitamin D in the HMF group to meet the recommended dietary allowances. MAIN OUTCOMES AND MEASURES: The primary outcome was the weight gain until discharge from the hospital or 40 weeks' postmenstrual age, whichever was earlier; the prespecified noninferiority margin was 2 g/kg/d. Secondary outcomes included morbidities such as necrotizing enterocolitis, feed intolerance, and extrauterine growth restriction (<10th percentile on the Fenton chart at 40 weeks' postmenstrual age). RESULTS: Of the 123 neonates enrolled, 60 and 63 were randomized to the PTF and HMF groups, respectively. The mean gestation (30.5 vs 29.9 weeks) and birth weight (1161 vs 1119 g) were comparable between the groups. There was no difference in the mean (SD) weight gain between the PTF and HMF groups (15.7 [3.9] vs 16.3 [4.0] g/kg/d; mean difference, -0.5 g/kg/d; 95% CI, -1.9 to 0.7). The lower bound of 95% CI did not cross the noninferiority margin. The incidence of feed intolerance was lower in the PTF group (1.4 vs 6.8 per 1000 patient-days; incidence rate ratio 0.19; 95% CI, 0.04 to 0.95), and fewer neonates required withholding of fortification for 24 hours or more (5% vs 22%; risk ratio, 0.22; 95% CI, 0.07 to 0.75). The incidence of necrotizing enterocolitis stage II or more (0 vs 5%) and extrauterine growth restriction (73% vs 81%) was comparable between the groups. CONCLUSIONS AND RELEVANCE: Fortification with preterm formula powder is not inferior to fortification with human milk fortifiers in preterm neonates. Given the possible reduction in feed intolerance and lower costs, preterm formula might be a better option for fortification, especially in resource-restricted settings. TRIAL REGISTRATION: Clinical Trial Registry, India Identifier: CTRI/2017/11/010593.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Chinnappan A, Sharma A, Agarwal R, et al. Fortification of Breast Milk With Preterm Formula Powder vs Human Milk Fortifier in Preterm Neonates: A Randomized Noninferiority Trial. JAMA Pediatr. 2021. PMID: 33970187. doi:10.1001/jamapediatrics.2021.0678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。